Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164193 | 1.00 | TSHR (0.55) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL4166867 | 1.00 | TSHR (0.55) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL30254792 | 1.00 | TSHR (0.55) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL4160109 | 1.00 | TSHR (0.55) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL18735392 | 0.92 | ALDH1A1 (0.48) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL17980377 | 0.91 | GPR84 (0.61) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL7752967 | 0.91 | GPR84 (0.55) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL16044475 | 0.90 | TSHR (0.59) | TSHRALDH1A1NAAAFAAHHCAR2 | |
| SCHEMBL17980418 | 0.87 | GPR84 (0.61) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL9002350 | 0.86 | FAAH (0.61) | TSHRNAAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104852-B1 | COMPOSITIONS AND METHODS FOR TREATING AGING AND AGE-RELATED DISEASES AND SYMPTOMS | UNIV CALIFORNIA (US) | 2024-08-14 | — | — | EP | claimed |
| US-11591658-B2 | Methods for sub-typing and treating cancer | HI-STEM GGMBH (DE) | 2023-02-28 | — | — | US | claimed |
| CN-113082009-A | Compositions and methods for treating aging and age-related diseases and conditions | 加利福尼亚大学董事会 | 2021-07-09 | — | — | CN | claimed |
| US-20190192470-A1 | Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms | UNIV CALIFORNIA (US) | 2019-06-27 | — | — | US | claimed |
| US-20160354334-A1 | Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-08 | — | — | US | claimed |
| EP-3980001-B1 | SUSTAINED-RELEASE COMPOSITIONS OF ALPHA-KETOGLUTARATE | PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024123738-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES RESPONSIVE TO AKG-VITAMIN B COADMINISTRATION | PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) | 2024-06-13 | — | — | WO | disclosed |
| US-20240094216-A1 | ODD CHAIN FATTY ACID THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | UNIVERSITY OF SOUTH CAROLINA | 2024-03-21 | — | — | US | disclosed |
| US-11802103-B2 | Process of making calcium alpha-ketoglutarate | PONCE DE LEON HEALTH DESIGNATED ACTIVITY COMPANY (IE) | 2023-10-31 | — | — | US | disclosed |
| US-20230265432-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | Sanford Burnham Prebys Medical Discovery Institute | 2023-08-24 | — | — | US | disclosed |
| CN-116492326-A | Preparation for prolonging life and health period | 巴克老龄化研究所 | 2023-07-28 | — | — | CN | disclosed |
| US-11591658-B2 | Methods for sub-typing and treating cancer | HI-STEM GGMBH (DE) | 2023-02-28 | — | — | US | disclosed |
| CN-106659701-A | Ketobutyrate compounds and compositions for treating age-related symptoms and diseases | 加尼福尼亚大学董事会 | 2017-05-10 | — | — | CN | disclosed |
| US-20150240215-A1 | METHOD TO PRODUCE VIRUS IN CULTURED CELLS SUPPLEMENTED WITH ALPHA-KETOGLUTARATE | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-08-27 | — | — | US | disclosed |
| WO-2013158706-A1 | METHOD TO PRODUCE VIRUS IN CULTURED CELLS SUPPLEMENTED WITH ALPHA-KETOGLUTARATE | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20090005437-A1 | Alpha-Ketoglutarates and Their Use as Therapeutic Agents | UNIVERSITY OF STRATHCLYDE (GB) | 2009-01-01 | — | — | US | disclosed |
| US-20090005437-A1 | Alpha-Ketoglutarates and Their Use as Therapeutic Agents | UNIVERSITY OF STRATHCLYDE (GB) | 2009-01-01 | — | — | US | disclosed |
| US-20090005437-A1 | Alpha-Ketoglutarates and Their Use as Therapeutic Agents | UNIVERSITY OF STRATHCLYDE (GB) | 2009-01-01 | — | — | US | disclosed |
| EP-1778616-A1 | ALPHA-KETOGLUTARATES AND THEIR USE AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006016143-A1 | ALPHA-KETOGLUTARATES AND THEIR USE AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240094216-A1 | ODD CHAIN FATTY ACID THERAPY FOR THE TREATMENT OF MITOCHONDRIAL DISEASES | NDUFAB1, OAT, CPT2 | TSHR 3971/4885GPR84 1994/4885PPARG 302/4885 |
| US-20160354334-A1 | Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms | GLA, GCDH, HAGH | TSHR 4583/4885GPR84 2714/4885PPARG 134/4885 |
| US-20090005437-A1 | Alpha-Ketoglutarates and Their Use as Therapeutic Agents | HIF1A, HIF1AN, EGLN3 | TSHR 3662/4885GPR84 492/4885PPARG 40/4885 |
| US-11591658-B2 | Methods for sub-typing and treating cancer | BCAT1, BCAT2, MLLT1 | TSHR 4620/4885GPR84 1312/4885PPARG 2160/4885 |
| US-11802103-B2 | Process of making calcium alpha-ketoglutarate | HOGA1, OGDH, GLS | TSHR 4838/4885GPR84 3811/4885PPARG 2577/4885 |
| US-20190192470-A1 | Compositions and Methods for Treating Aging and Age-Related Diseases and Symptoms | GCDH, GLA, GRHPR | TSHR 4684/4885GPR84 2761/4885PPARG 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.